EPIQ Partners’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-10,366
| Closed | -$36.3K | – | 77 |
|
|
2024
Q3 | $36.3K | Buy |
+10,366
| New | +$36.3K | 0.02% | 77 |
|
|
2024
Q2 | – | Sell |
-10,071
| Closed | -$73.9K | – | 74 |
|
|
2024
Q1 | $73.9K | Hold |
10,071
| – | – | 0.05% | 74 |
|
|
2023
Q4 | $37.7K | Buy |
+10,071
| New | +$37.7K | 0.03% | 68 |
|
|
2023
Q3 | – | Sell |
-10,071
| Closed | -$47.9K | – | 70 |
|
|
2023
Q2 | $47.9K | Buy |
+10,071
| New | +$47.9K | 0.03% | 76 |
|
|
2023
Q1 | – | Sell |
-71,521
| Closed | -$722K | – | 78 |
|
|
2022
Q4 | $722K | Sell |
71,521
-1,245
| -2% | -$12.6K | 0.48% | 46 |
|
|
2022
Q3 | $1.63M | Buy |
72,766
+3,973
| +6% | +$89.1K | 1.01% | 37 |
|
|
2022
Q2 | $1.71M | Buy |
68,793
+10,985
| +19% | +$272K | 1.04% | 36 |
|
|
2022
Q1 | $2.24M | Buy |
57,808
+9,205
| +19% | +$357K | 1.21% | 34 |
|
|
2021
Q4 | $2.84M | Sell |
48,603
-235
| -0.5% | -$13.8K | 1.52% | 23 |
|
|
2021
Q3 | $2.9M | Sell |
48,838
-847
| -2% | -$50.2K | 1.33% | 27 |
|
|
2021
Q2 | $4.31M | Buy |
49,685
+2,930
| +6% | +$254K | 2.16% | 13 |
|
|
2021
Q1 | $3.86M | Buy |
46,755
+3,287
| +8% | +$271K | 2.21% | 14 |
|
|
2020
Q4 | $3.95M | Buy |
43,468
+5,205
| +14% | +$473K | 2.75% | 10 |
|
|
2020
Q3 | $1.7M | Buy |
+38,263
| New | +$1.7M | 1.28% | 32 |
|